CureVac BV said on Friday it raised $213.3 million in its initial public offering in New York, setting the stage for the first stock market debut of a company developing a potential vaccine to combat the coronavirus.
The German biotechnology firm, backed by Microsoft Corp founder and billionaire Bill Gates, sold 13.33 million shares at $16 apiece, the top end of its indicated price range of between $14 and $16 per share.
CureVac is researching how to use messenger RNA to treat a series of diseases, including the coronavirus. It is an experimental approach that has also been adopted by some of its peers, including Moderna Inc and BioNTech SE. Bank of America, Jefferies, and Credit Suisse are lead underwriters on the IPO. CureVac shares are due to start trading on Nasdaq on Friday under the symbol ‘CVAC’.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Coronavirus vaccine developer CureVac raises $213 million in IPO: sourceCureVac BV raised $213 million in its initial public offering (IPO) in New York on Thursday, a person familiar with the matter said, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the coronavirus.
Weiterlesen »
Coronavirus vaccine developer CureVac raises $213 million in IPO: sourceCureVac BV raised $213 million in its initial public offering (IPO) in New York on Thursday, a person familiar with the matter said, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the coronavirus.
Weiterlesen »
Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK for trialU.S. drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
Weiterlesen »
The U.S. has already invested billions on potential coronavirus vaccines. Here's where the deals standThe U.S. has doled out billions to develop a vaccine against the coronavirus, locking in a minimum of 800 million doses so far.
Weiterlesen »
People Who Refuse COVID-19 Vaccine Could Be Barred from Work and SchoolsThe coronavirus vaccine could be forced on Americans, says Stanford Law School professor Hank Greely.
Weiterlesen »
What we know -- and don't know -- about Russia's 'Sputnik V' vaccineRussia raised eyebrows on Tuesday when it announced the world's first approved coronavirus vaccine for public use. Details about the research behind the vaccine are limited, but here's what we know so far.
Weiterlesen »